Effect of high rosuvastatin dose on outcome in patients with large artery atherosclerotic stroke
10.3969/j.issn.1009-0126.2018.03.015
- VernacularTitle:大动脉粥样硬化型脑卒中患者应用大剂量瑞舒伐他汀的临床观察
- Author:
Qiuwan LIU
1
;
Zhuqing WU
;
Xiaoqiang WANG
;
Sen QUN
;
Juncang WU
Author Information
1. 230011,安徽医科大学附属合肥医院 合肥市第二人民医院新区神经内科
- Keywords:
atherosclerosis;
stroke;
C-reactive protein;
platelet aggregation inhibitors
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2018;20(3):278-281
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of high rosuvastatin dose on outcome in patients with large artery atherosclerotic stroke (LAAS).Methods Eighty-two LAAS patients were randomly divided into high rosuvastatin dose group (n=39) and routine rosuvastatin dose group (n=43).Their serum blood lipid level and inflammatory indexes were measured and their clinical outcome was assessed.Results No significant difference was found in mortality,recurrence and hemorrhagic transformation between the two groups (P＞0.05).The rate of improved outcome was significantly higher in high rosuvastatin dose group than in routine rosuvastatin dose group (84.62％ vs 65.12％,P=0.04).The serum hs-CRP level was significantly lower in routine rosuvastatin dose group and high rosuvastatin dose group after treatment than before treatment (0.56±0.60 mg/L vs 0.70±0.68 mg/L,P=0.01;0.22±0.29 mg/L vs 0.69±0.58mg/L,P=0.00) and in high rosuvastatin dose group than in routine rosuvastatin dose group after treatment than before treatment (0.22±0.29 mg/L vs 0.56±0.60 mg/L,P=0.00).The rate of LDL C＜1.8 mmol/L and non HDL-C＜2.6 mmol/L was significantly higher in high rosuvastatin dose group than in rosuvastatin dose group after treatment (69.23％ vs 46.51％,P=0.04;66.67％ vs 41.86％,P=0.03).No significant adverse reactions occurred in both groups.Conclusion High rosuvastatin dose can effectively increase the blood lipid level,reduce the serum hs-CRP level,and improve the clinical outcome in LAAS patients.
